Prospective Variation of Cytokine Trends during COVID-19: A Progressive Approach from Disease Onset until Outcome.

Prospective Variation of Cytokine Trends during COVID-19: A Progressive Approach from Disease Onset until Outcome.

Publication date: Oct 01, 2024

COVID-19 is characterized by pronounced hypercytokinemia. The cytokine switch, marked by an imbalance between pro-inflammatory and anti-inflammatory cytokines, emerged as a focal point of investigation throughout the COVID-19 pandemic. However, the kinetics and temporal dynamics of cytokine release remain contradictory, making the development of new therapeutics difficult, especially in severe cases. This study collected serum samples from SARS-CoV-2 infected patients at 72 h intervals and monitored them for various cytokines at each timepoint until hospital discharge or death. Cytokine levels were analyzed based on time since symptom onset and patient outcomes. All cytokines studied prospectively were strong predictors of mortality, particularly IL-4 (AUC = 0. 98) and IL-1β (AUC = 0. 96). First-timepoint evaluations showed elevated cytokine levels in the mortality group (p < 0. 001). Interestingly, IFN-γ levels decreased over time in the death group but increased in the survival group. Patients who died exhibited sustained levels of IL-1β and IL-4 and increased IL-6 levels over time. These findings suggest cytokine elevation is crucial in predicting COVID-19 mortality. The dynamic interplay between IFN-γ and IL-4 highlights the balance between Th1/Th2 immune responses and underscores IFN-γ as a powerful indicator of immune dysregulation throughout the infection.

Open Access PDF

Concepts Keywords
Covid Adult
Hospital Aged
Hypercytokinemia COVID-19
Serum COVID-19
cytokine storm
Cytokines
Cytokines
death
Female
Humans
hyperinflammation
inflammation
Interferon-gamma
Interferon-gamma
Interleukin-1beta
Interleukin-1beta
Interleukin-4
Interleukin-4
Interleukin-6
Interleukin-6
Male
Middle Aged
Prospective Studies
SARS-CoV-2
SARS-CoV-2
severity

Semantics

Type Source Name
disease MESH COVID-19
disease MESH hypercytokinemia
pathway REACTOME Release
disease MESH death
disease IDO symptom
drug DRUGBANK Binetrakin
drug DRUGBANK Isoxaflutole
disease MESH infection
drug DRUGBANK Coenzyme M
disease MESH inflammation
disease IDO process
disease MESH clinical importance
disease IDO production
disease MESH viral diseases
disease MESH cardiomyopathies
disease MESH lung injury
disease IDO role
disease MESH fibrosis
disease IDO cell
disease IDO host
drug DRUGBANK Angiotensin II
disease IDO immune response
disease MESH complications
drug DRUGBANK Aspartame
disease IDO blood
disease MESH hypertension
disease MESH Diabetes mellitus
disease MESH Dyslipidemia

Original Article

(Visited 1 times, 1 visits today)